A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 23, 2018

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2022

Conditions
Cancer - Acute Myeloid Leukemia
Interventions
DRUG

Venetoclax

tablet, oral

DRUG

Dinaciclib

intravenous

Trial Locations (13)

3168

Monash Medical Centre /ID# 202762, Melbourne

4215

Gold coast University Hospital /ID# 202759, Southport

7000

Royal Hobart Hospital /ID# 202763, Hobart

28034

Hospital Universitario Ramon y Cajal /ID# 201729, Madrid

37711

Hospital Universitario de Salamanca /ID# 201728, Salamanca

43210

The Ohio State University /ID# 200668, Columbus

46026

Hospital Universitario y Politecnico La Fe /ID# 202318, Valencia

60637

The University ofChicago /ID# 200017, Chicago

72205

University of Arkansas /ID# 200016, Little Rock

77030

University of Texas MD Anderson Cancer Center /ID# 205215, Houston

90095

David Geffen School of Medicin /ID# 200015, Los Angeles

21201-1544

University of Maryland School of Medicine /ID# 204015, Baltimore

27157-0001

Wake Forest Baptist Medical Center /ID# 200288, Winston-Salem

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

AbbVie

INDUSTRY